Please ensure Javascript is enabled for purposes of website accessibility

Why NxStage Medical, Inc. Got Hammered Today

By Brian Orelli, PhD - May 9, 2017 at 12:02PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

A cut in 2017 outlook for home dialysis products has investors disappointed.

What happened

NxStage Medical (NXTM) is down almost 15% at 12:21 p.m. EDT after releasing first-quarter earnings in which the company cut its 2017 outlook for the future.

So what

The first quarter wasn't so bad, with NxStage Medical posting a 9% year-over-year increase in revenue. The revenue growth didn't drop to the earnings line as the company spent more on selling and marketing expenses as well as research and development. Both of those may pay off in the long run, but for now, NxStage posted a net loss of $0.02 per share, the same as in the year-ago quarter.

It's where the growth came from and expectations that fosters that's causing investors angst today. NxStage Medical has made a big push into dialysis at home, but growth for that segment came in at just 10% year over year, causing management to revise its 2017 home revenue growth target to be between 10% and 13%, down from a previous target of 15%.

Patient's arm while on dialysis

Image source: Getty Images.

The company also announced an indefinite delay in the launch of its peritoneal dialysis system that was scheduled to be launched by the end of the year. Management still thinks it can get to market before anyone else, but depending on how long the delay takes, it could have a negative impact on revenue growth next year.

Now what

While this year looks like it's going to be a bit of a disappointment for NxStage, most of that has to do with the high expectations the company set. Overall, NxStage looks well poised to take advantage of long-term growth in home dialysis. As long as it can develop new products to stay ahead of the curve, NxStage should be OK in the long run.

Brian Orelli has no position in any stocks mentioned. The Motley Fool owns shares of and recommends NxStage Medical. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Nxstage Medical, Inc. Stock Quote
Nxstage Medical, Inc.
NXTM

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
397%
 
S&P 500 Returns
128%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/19/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.